Analgesics in India has demonstrated sustained momentum in 2026, with expected retail current value growth of 7% and sales set to reach INR71,301 million, outpacing the broader Asia Pacific region due to resilient demand for self-managed pain relief, and favourable economic conditions, such as a real GDP increase of 7% and inflation at 4%. The robust attractiveness of this environment is reinforced by a large and growing population, rising consumer expenditure, and expanding usage occasions linked to urbanisation, longer working hours, and active lifestyles. These factors collectively underpin a strong forecast trajectory, as reflected in a projected retail current value CAGR of 6% through to 2031. Major shifts in purchasing behaviour are being driven by the rapid adoption of e-commerce and quick commerce, which have transformed the buying process into an impulse-led, on-demand experience, while pharmacies remain foundational due to their trusted status and extensive reach. Leading brands are securing competitive advantage by innovating with convenient, portable formats and by expanding portfolios to address specific pain types, including nerve and muscular pain, while regulatory changes further steer the focus towards established, safety-led formulations. Success in analgesics will depend on optimising visibility across both physical and digital channels, leveraging trusted brand equity, and responding quickly to evolving consumer needs with targeted, multi-format solutions.
Delivery:
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Overview:
Understand the latest market trends and future growth opportunities for the Analgesics industry in India with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Analgesics industry in India, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
The Analgesics in India report includes:
- Analysis of key supply-side and demand trends
- Detailed segmentation of international and local products
- Historic volume and value sizes, company and brand market shares
- Five year forecasts of market trends and market growth
- Robust and transparent research methodology, conducted in-country
This report answers:
- What is the market size of Analgesics in India?
- Which are the leading brands in Analgesics in India?
- How are products distributed in Analgesics in India?
- How has the regulatory and operating environment for Analgesics changed in India?
- How are considerations such as stress, self-medication and shifting consumer lifestyles shaping demand for Analgesics
- How significant are wider health concerns and consumer awareness in determining sales?
- Where is future growth expected to be most dynamic?
Key Data Insights
Key Industry Trends
Emami accelerates with quick commerce, reshaping pain relief access
Dolo leverages brand equity to expand into on-the-go pain relief
Neurobion creates new pain niches with targeted roll-on innovation
Chart 1 Value Sales 2021-2031
Chart 2 Value Sales by Category 2026
More brands expected to develop targeted solutions as consumer awareness of pain deepens
Topical formats set to gain traction as daily routines drive usage frequency
Wearable devices and digital therapeutics likely to redefine pain management approaches
Chart 1 Forecast Value Sales 2021-2031
Chart 2 Forecast Value Sales by Category 2026-2031
Emami leverages portfolio strength as the competition diversifies
Companies focus on portfolio expansion
Chart 1 Company Shares 2026
Chart 2 Brand Shares 2026
Pharmacies sustains trust as the anchor distribution channel
E-commerce and quick commerce redefine impulse access to pain relief
Chart 1 Retail Channels 2021-2026
Indication-specific segmentation reshapes topical analgesics
Recent launches target nerve pain and portable formats
Targeted propositions and portfolio breadth drive commercial gains
Chart 1 Real GDP Growth 2021-2031
Chart 2 Inflation 2021-2031
Chart 1 Population 2021-2031
Chart 2 Population by Generation 2026
Chart 3 Consumer Expenditure 2021-2031
Country Reports Disclaimer
The following categories and subcategories are included:
Analgesics
-
-
- Adult Acetaminophen
- Adult Aspirin
- Adult Combination Products - Analgesics
- Adult Diclofenac
- Adult Dipyrone
- Adult Ibuprofen
- Adult Ketoprofen
- Adult Naproxen
- Adult OTC Triptans
-
- Paediatric Acetaminophen
- Paediatric Aspirin
- Paediatric Combination Products - Analgesics
- Paediatric Dipyrone
- Paediatric Ibuprofen
- Paediatric Naproxen
-
- Acetaminophen
- Aspirin
- Combination Products - Analgesics
- Diclofenac
- Dipyrone
- Ibuprofen
- Ketoprofen
- Naproxen
- OTC Triptans
-
- Topical Analgesics/Anaesthetic
Analgesics
Analgesics cover systemic and topical pain relievers. Products which include a pain-relief ingredient in addition to another core function are excluded (e.g. a sore throat remedy which includes paracetamol is excluded from the analgesics and instead is included in pharyngeal remedies).
See all of our definitionsWhy buy this report?
- Gain competitive intelligence about market leaders
- Track key industry trends, opportunities and threats
- Inform your marketing, brand, strategy and market development, sales and supply functions
This report originates from Passport, our Analgesics research and analysis database.
NEW REPORT GUARANTEE
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!